A GLP-1 quiets hunger, but it doesn't touch the reasons eating became about more than hunger — and it can't tell you who you are when the weight comes off faster than your self-image updates. Plenty of people do well on these medications with no mental-health support at all. Plenty of others find that a good therapist is the difference between losing weight and actually feeling better. This is a guide to when that support helps, what kinds of help exist, and how to actually get it.
First, the reassuring part — and the part to watch
If you're worried that a weight-loss medication might drag your mood down, the population-level evidence is broadly reassuring. In a large 2025 real-world study of adults with obesity, GLP-1 use was associated with lower risks of depression and of suicidal ideation or attempts compared with other anti-obesity medications — though note these were secondary outcomes of a study designed around heart and kidney events, so they're a reassuring signal rather than the study's main finding (Tang et al., Diabetes, Obesity & Metabolism, 2025, DOI (external link), via PubMed). And in a 2025 randomized trial in people who already had major depressive disorder, semaglutide did not worsen depressive symptoms or the frequency of suicidal ideation — it was considered safe for that group. That trial was small and short — 72 people, 16 weeks, oral semaglutide 14 mg — so it's early evidence rather than the last word (Badulescu et al., Med, 2025, DOI (external link), via PubMed).
That said, the picture isn't uniform, which is why mood is worth watching. A 2024 analysis of a global drug-safety database found a mixed signal — higher reporting of suicidal ideation for some GLP-1s alongside lower reporting of suicide attempts and completed suicide — and the authors were explicit that this kind of data cannot establish cause either way (McIntyre et al., , 2024, , via PubMed). Regulators reviewed similar signals and did not establish a causal link: the FDA's January 2024 preliminary evaluation found no evidence that these medicines cause suicidal thoughts or actions (while not ruling out a small risk), and the European Medicines Agency's safety committee concluded in April 2024 that the available evidence does not support a causal association. The practical takeaway isn't alarm — it's that , the same as any other symptom.